Nucleo
Nucleo is a YC Fall 2025 (F25) company. Based in San Francisco, CA, USA. Team of 2.
About Nucleo
Summary
Nucleo automates CT scan analysis for oncologists and radiologists, covering tumor lesion sizing, target versus non-target lesion classification per RECIST criteria, and body composition assessment for sarcopenia. The platform replaces manual segmentation and interpretation work that clinicians perform today. Hospitals including Stanford, Cedars-Sinai, UCI Health, and Weill Cornell use it to support tumor characterization and treatment decisions.
Go-to-market
Nucleo sells to hospital oncology and radiology departments through a sales-led motion, with prospects booking a demo directly via the website.
From the Y Combinator listing
The first Agentic platform for Oncology
We help oncologists and radiologists extract insights from CT scans to support tumor characterization and treatment. The hospitals we work with include Stanford Hospital, Cedars-Sinai (the largest hospital in California), UCI Health, and Weill Cornell.
Facts
- Healthcare / Healthcare
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
- Luca Pegolotti
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works